RESUMO
Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection. International guidelines on menopausal hormone therapy (MHT) do not specify on progestogen type, dosage, route of application and duration of safe use. At the same time, the debate on bioidentical hormones including micronized progesterone increases. Based on a systematic literature review on micronized progesterone for endometrial protection, an international expert panel's recommendations on MHT containing micronized progesterone are as follows: (1) oral micronized progesterone provides endometrial protection if applied sequentially for 12-14 days/month at 200 mg/day for up to 5 years; (2) vaginal micronized progesterone may provide endometrial protection if applied sequentially for at least 10 days/month at 4% (45 mg/day) or every other day at 100 mg/day for up to 3-5 years (off-label use); (3) transdermal micronized progesterone does not provide endometrial protection.
Assuntos
Endométrio/efeitos dos fármacos , Terapia de Reposição de Estrogênios/métodos , Menopausa/efeitos dos fármacos , Progesterona/administração & dosagem , Progestinas/administração & dosagem , Administração Cutânea , Administração Intravaginal , Administração Oral , Terapia de Reposição de Estrogênios/normas , Feminino , Humanos , Guias de Prática Clínica como Assunto , Progesterona/normas , Progestinas/normas , Útero/efeitos dos fármacos , VaginaRESUMO
Complications resulting from the use of compounded medications have become a troubling trend nationwide. There is a significant potential for patients to suffer serious harm from the use of substandard medications prepared by compounding pharmacies, and the reality of this problem has been demonstrated in several well-publicized incidences of serious medical complications, including patient deaths, that directly resulted from the use of medications prepared at compounding pharmacies. Unlike US Food and Drug Administration (FDA)-approved drugs, compounded products are not required to meet evidentiary standards for establishing safety and efficacy. Moreover, these products are not held to Good Manufacturing Practices, which require regular inspections, quality control testing, and rejection of material not meeting specifications. Physicians, as well as other prescribers, need to be aware that when a patient suffers harm from using a compounded medication, those injured patients may bring negligence and malpractice claims, not only against the pharmacy and the pharmacist responsible for preparing the medication, but also against the prescribing physician and the physician's practice. Consequently, the best way for physicians to manage professional risk and avoid both litigation and potential negative patient outcomes related to compounded pharmaceuticals is to not use these products if there is an FDA-approved product available. However, if the use of a compounded medication is medically necessary, then physicians should adhere to the FDA guidance concerning traditional compounding. Moreover, it would be prudent for any physician who intends to either resell or participate in the distribution of compounded products beyond the direct treatment of their patients to consider obtaining the appropriate insurance coverage for this activity.
Assuntos
Composição de Medicamentos , Padrões de Prática Médica , Caproato de 17 alfa-Hidroxiprogesterona , Aprovação de Drogas , Composição de Medicamentos/efeitos adversos , Composição de Medicamentos/normas , Humanos , Hidroxiprogesteronas/administração & dosagem , Hidroxiprogesteronas/normas , Seguro de Responsabilidade Civil , Responsabilidade Legal , Imperícia , Obstetrícia/legislação & jurisprudência , Padrões de Prática Médica/legislação & jurisprudência , Progestinas/administração & dosagem , Progestinas/normas , Medição de Risco , Estados UnidosRESUMO
The purpose of this study was to investigate the quality of hydroxyprogesterone caproate (HPC) active pharmaceutical ingredient (API) sources that may be used by compounding pharmacies, compared to the FDA-approved source of the API; and to investigate the quality of HPC injection samples obtained from compounding pharmacies in the US, compared to the FDA-approved product (Makena(®)). Samples of API were obtained from every source confirmed to be an original manufacturer of the drug for human use, which were all companies in China that were not registered with FDA. Eight of the ten API samples (80%) did not meet the impurity specifications required by FDA for the API used in the approved product. One API sample was found to not be HPC at all; additional laboratory testing showed that it was glucose. Thirty samples of HPC injection obtained from compounding pharmacies throughout the US were also tested, and eight of these samples (27%) failed to meet the potency requirement listed in the USP monograph for HPC injection and/or the HPLC assay. Sixteen of the thirty injection samples (53%) exceeded the impurity limit set for the FDA-approved drug product. These results confirm the inconsistency of compounded HPC Injections and suggest that the risk-benefit ratio of using an unapproved compounded preparation, when an FDA-approved drug product is available, is not favorable.
Assuntos
Composição de Medicamentos/normas , Hidroxiprogesteronas/normas , Nascimento Prematuro/prevenção & controle , Progestinas/normas , Caproato de 17 alfa-Hidroxiprogesterona , Aprovação de Drogas , Composição de Medicamentos/métodos , Feminino , Humanos , Hidroxiprogesteronas/análise , Hidroxiprogesteronas/uso terapêutico , Injeções , Gravidez , Progestinas/análise , Progestinas/uso terapêutico , Controle de Qualidade , Estados Unidos , United States Food and Drug AdministrationRESUMO
Recent epidemiologic studies indicate that use of combined oral contraception is associated with a increase in the incidence of cardiovascular disease (venous thromboembolism, pulmonary embolism, myocardial infarction and stroke). The risk of cardiovascular disease is strongly related to estrogen dose, progestogen type and other factors for example thrombogenic mutations and cigarette smoking among female over age 35. The progestogen only contraception is safe alternative to combined hormonal contraception. Progestogen only pill (POP) has different levels of action (local and/or central) which may vary from one drug to another. As for the cardiovascular disease risk, progestogens are not considered to be risk factors. Desogestrel containing POP is advised in the following cases: bad tolerance of exogenous oestrogens; in order to counteract an endogenous hyperoestrogenosis; medical, metabolic or cardiovascular contraindications to estroprogestogen contraception. Lastly, POP should be used as a prime contraception in some particular situations (breast feeding, endometriosis, adenomyosis, cigarette smoking, contraception for older women). These recommendations present the actual system of care in that population of women in Poland.
Assuntos
Doenças Cardiovasculares/prevenção & controle , Anticoncepcionais Orais Sintéticos/administração & dosagem , Desogestrel/administração & dosagem , Progestinas/administração & dosagem , Saúde da Mulher , Fatores Etários , Anticoncepcionais Orais/normas , Anticoncepcionais Orais Sintéticos/normas , Desogestrel/normas , Feminino , Humanos , Capacitação em Serviço/normas , Programas Nacionais de Saúde/normas , Polônia , Progestinas/normas , Garantia da Qualidade dos Cuidados de Saúde/normas , Fatores de Risco , Sociedades Médicas/normas , Serviços de Saúde da Mulher/organização & administraçãoAssuntos
Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/uso terapêutico , Infecções Tumorais por Vírus/prevenção & controle , Neoplasias do Colo do Útero/prevenção & controle , Congressos como Assunto , Feminino , Ginecologia/normas , Humanos , Capacitação em Serviço/normas , Masculino , Programas Nacionais de Saúde/normas , Obstetrícia/normas , Polônia , Guias de Prática Clínica como Assunto , Prevenção Primária/normas , Progestinas/normas , Garantia da Qualidade dos Cuidados de Saúde/normas , Sociedades Médicas/normas , Neoplasias do Colo do Útero/virologiaRESUMO
PURPOSE OF REVIEW: In the practice of 'bioidentical hormone therapy', it is our belief that pharmacists are compounding bioidentical hormone therapy with the best intentions. These pharmacists are, however, ill informed regarding the lack of scientific underpinning associated with the efficacy and safety of the practice of bioidentical hormone therapy. It is the purpose of this review to systematically examine the scientific rigor of the arguments posed by the proponents of bioidentical hormone therapy, and to differentiate the practice of bioidentical hormone therapy from the legitimate practice of pharmacy compounding. RECENT FINDINGS: Most medical organizations have in essence refuted the bioidentical hormone therapy claims as unsubstantiated. The profession of pharmacy needs to address this issue in an authoritarian, scientific way, outside of the compounding issue. SUMMARY: Bioidentical or natural hormones are expected to have similar efficacy and safety profiles as the commercially available hormonal therapies that have been studied in clinical trials, regardless of whether the active principle hormones are compounded by individual pharmacies or manufactured by large companies. Estriol is a weak estrogen that is not Food and Drug Administration approved for use as a prescription drug in the United States; thus, clinical trials are necessary to demonstrate the efficacy and safety profile for estriol. Further, supplementary clinical trials are necessary to determine whether there are efficacy or safety differences between natural progesterone and synthetic progestin, as studies to date are inconclusive.
Assuntos
Composição de Medicamentos/normas , Terapia de Reposição de Estrogênios/efeitos adversos , Progestinas/efeitos adversos , Adulto , Aprovação de Drogas , Composição de Medicamentos/efeitos adversos , Estriol/efeitos adversos , Estriol/normas , Terapia de Reposição de Estrogênios/normas , Medicina Baseada em Evidências , Feminino , Humanos , Progestinas/normas , Estados UnidosRESUMO
The surprising results of the Women's Health Initiative (WHI) reported in 2002 had a profound effect on women as well as health care practitioners. The WHI was the largest, randomized clinical trial designed to determine if postmenopausal hormone use prevented cardiovascular disease as well as other age-related disorders in women. While observational studies suggested that postmenopausal use of estrogen could decrease cardiovascular risk by 40% to 50%, the WHI demonstrated that use of continuous-combined estrogen plus progestin was not cardioprotective and was even associated with increased health risks. The estrogen alone trial of the WHI is still in progress, leaving practitioners and some women still in a dilemma. This article addresses the WHI in the context of other studies and discusses possible reasons for the unexpected results.
Assuntos
Estrogênios/uso terapêutico , Progestinas/uso terapêutico , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/fisiopatologia , Doenças Cardiovasculares/prevenção & controle , Quimioterapia Combinada , Terapia de Reposição de Estrogênios/normas , Estrogênios/normas , Feminino , Humanos , Pós-Menopausa/efeitos dos fármacos , Pós-Menopausa/fisiologia , Prevalência , Progestinas/normas , Ensaios Clínicos Controlados Aleatórios como Assunto , Medição de Risco/normasRESUMO
Several progestin-only long acting contraceptives are currently available in the form of implants or injectables. Vaginal rings are another contraceptive option in the final stages of development. These steroid-containing polymer rings are placed in the vagina, providing relatively constant drug release, thus allowing for lower effective doses. Vaginal rings have the advantage of being user-controlled and non-provider dependent, and their use is non-coital related. The first clinical study with medroxyprogesterone acetate vaginal rings was published in 1970. Since then numerous clinical trials testing different steroids and doses have followed. A large Phase III multicenter clinical trial with a levonorgestrel ring, releasing 20 microg/day, was coordinated and sponsored by WHO. The cumulative one-year pregnancy rate was 4. 5%. The principal reasons for discontinuation were menstrual disturbances (17.2%), followed by frequent expulsion of the ring (7. 1%), and vaginal symptoms (6.0%). The finding of erythematous lesions in the vagina in some women has led to the development of a more flexible device. Collaboration with industry should facilitate the manufacture of a redesigned levonorgestrel ring with a higher release rate. The Population Council is also developing a vaginal ring containing Nestorone for 6 months of continuous use. Ovulation inhibition was achieved in over 97% of the segments studied, with rings releasing either 50, 75, or 100 microg/day. No pregnancies occurred in women using the low-dose ring, while one pregnancy each occurred in the intermediate- and high-dose ring groups for a 6-month cumulative pregnancy rate of 0.0, 1.9, and 2.1%. Bleeding irregularities were common. Nestorone is orally inactive; therefore this ring is also excellent for use in lactating women.
Assuntos
Anticoncepcionais Femininos/administração & dosagem , Progestinas/administração & dosagem , Administração Intravaginal , Anticoncepcionais Femininos/sangue , Anticoncepcionais Femininos/normas , Preparações de Ação Retardada/farmacocinética , Preparações de Ação Retardada/normas , Implantes de Medicamento/farmacocinética , Implantes de Medicamento/normas , Feminino , Humanos , Gravidez , Progestinas/sangue , Progestinas/normasRESUMO
Progestin implants for contraception are highly effective, safe, and the most convenient choice for many women. Progestin implants currently on the market, preparing for launch, or under investigation are reviewed here. Their basic galenic and pharmacokinetic features, as well as their contraceptive effectiveness, are described. The first progestin-only contraceptive implant placed on the market was Norplant, a multiunit system. Since then, several single- and double-rod implants have been developed, each using one of four different progestins: levonorgestrel, etonogestrel, Nestorone and nomegestrol acetate. Jadelle is similar to Norplant but consists of only two, rather than six, Silastic rods to simplify insertion and removal; nevertheless, levonorgesterel serum levels are identical, and performance is the same for both systems. The single implant systems reviewed here are: Implanon with a 3-year duration; Nestorone implants for breast feeding and non-breast feeding women lasting up to 2 years; and Uniplant, which is effective for 1 year. The advantages and disadvantages of progestin implants, the importance of counseling for increasing user satisfaction, and the future outlook for this contraceptive method are also discussed.
Assuntos
Progestinas/normas , Administração Intravaginal , Anticoncepcionais Femininos/administração & dosagem , Anticoncepcionais Femininos/farmacocinética , Anticoncepcionais Femininos/normas , Preparações de Ação Retardada/farmacocinética , Preparações de Ação Retardada/normas , Implantes de Medicamento/farmacocinética , Implantes de Medicamento/normas , Feminino , Humanos , Gravidez , Progestinas/administração & dosagem , Progestinas/farmacocinéticaRESUMO
OBJECTIVE: Tibolone has been shown to alleviate climacteric symptoms. This study was designed to compare the effect of tibolone (Livial, 2.5 mg daily) on different climacteric complaints and its impact on the endometrium, determined by vaginal ultrasound, with that of conjugated estrogens (Premarin, 0.625 mg daily) continuously for 6 months in combination with the progestogen medrogestone (Colpron, 2 x 5 mg daily for 12 days each month). METHODS: One hundred and twenty-nine postmenopausal women were recruited and the severity of climacteric symptoms as well as endometrial thickness were recorded at the pre-trial examination and after 1, 3, and 6 months. RESULTS: With the exception of vertigo, mood depression, mood disorder, loss of libido, and dryness of skin, where tibolone was found to be more effective than conjugated estrogens/medrogestone, climacteric symptoms improved significantly in both groups over the 6-month study period. Endometrial thickness did not increase significantly in the tibolone group, whereas in the conjugated estrogens/medrogestone group there was a highly significant increase after 1 month and still a trend towards significance after 6 months. Recurrence of vaginal bleeding occurred significantly less frequently in the tibolone group than in the comparison group. CONCLUSION: Tibolone seems to offer a complete treatment of the climacteric complaints whilst avoiding some of the problems associated with classical hormone replacement therapy.
Assuntos
Climatério/efeitos dos fármacos , Estrogênios/uso terapêutico , Norpregnenos/uso terapêutico , Progestinas/uso terapêutico , Climatério/fisiologia , Relação Dose-Resposta a Droga , Endométrio/anatomia & histologia , Endométrio/diagnóstico por imagem , Endométrio/efeitos dos fármacos , Estrogênios/efeitos adversos , Estrogênios/normas , Feminino , Humanos , Incidência , Pessoa de Meia-Idade , Norpregnenos/efeitos adversos , Norpregnenos/normas , Progestinas/efeitos adversos , Progestinas/normas , Inquéritos e Questionários , Fatores de Tempo , Ultrassonografia , Hemorragia Uterina/tratamento farmacológico , Hemorragia Uterina/epidemiologiaAssuntos
Terapia de Reposição de Estrogênios/normas , Progestinas/normas , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/prevenção & controle , Ensaios Clínicos como Assunto , Hiperplasia Endometrial/epidemiologia , Hiperplasia Endometrial/prevenção & controle , Neoplasias do Endométrio/epidemiologia , Neoplasias do Endométrio/prevenção & controle , Feminino , Humanos , Incidência , Metabolismo dos Lipídeos , Progestinas/efeitos adversos , Progestinas/uso terapêutico , Fatores de Risco , Estados Unidos/epidemiologiaRESUMO
OBJECTIVE: To evaluate whether the efficacy of naltrexone administration in patients with hypothalamic amenorrhea correlates to the response to an acute naloxone test. DESIGN: Thirty patients with hypothalamic amenorrhea associated with weight loss were studied. After naloxone test (4 mg in bolus IV) patients were divided into two groups: group A, nonresponsive (n = 15) and group B, responsive (n = 15). Group A underwent two cycles of hormonal replacement therapy with E2 patches and medroxyprogesterone acetate. Then all patients were administered naltrexone at the dosage 50 mg/d orally for 6 months. A third group of 10 amenorrheic patients were treated with oral placebo with the same schedule. RESULTS: Plasma gonadal steroid levels increased in all patients and in 24 of 30 patients the menstrual bleeding occurred within 90 days from the beginning of treatment. After 6 months from naltrexone discontinuation, 18 of 24 patients still showed the occurrence of menstrual cycles. Luteinizing hormone plasma levels and LH pulse amplitude increased after 3 months of treatment and remained unchanged 6 months after naltrexone suspension. Plasma FSH levels did not show any change in any patient. The body mass index increased after 3 months in all patients who menstruated. Patients treated with placebo did not show any significant change in gonadotropins and gonadal steroid plasma levels. CONCLUSIONS: The present study supports the efficacy of naltrexone therapy for patients with hypothalamic amenorrhea either responsive or nonresponsive to naloxone test.
Assuntos
Amenorreia/tratamento farmacológico , Amenorreia/fisiopatologia , Ciclo Menstrual/fisiologia , Naltrexona/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Redução de Peso/fisiologia , Administração Oral , Amenorreia/sangue , Índice de Massa Corporal , Relação Dose-Resposta a Droga , Terapia de Reposição de Estrogênios/normas , Estrogênios/normas , Feminino , Hormônio Foliculoestimulante/sangue , Humanos , Hormônio Luteinizante/sangue , Naloxona , Naltrexona/administração & dosagem , Naltrexona/normas , Antagonistas de Entorpecentes/administração & dosagem , Antagonistas de Entorpecentes/normas , Progestinas/normasRESUMO
The ideal preparation for estrogen replacement therapy has been the object of intensive research for decades, and the search continues. More than 40 new products are in development in the United States, the United Kingdom, and Europe. Most are transdermal, which reflects the growing acceptance of patch technology at a time when the overwhelming majority of women who use estrogen replacement take oral formulations. Most of the new oral formulations are a combination of estrogen and progestin. Aspects of transdermal and oral estrogen are discussed, including the advantages and disadvantages for use in women with concomitant medical conditions.
Assuntos
Sistemas de Liberação de Medicamentos , Terapia de Reposição de Estrogênios/normas , Estrogênios/administração & dosagem , Progestinas/administração & dosagem , Administração Cutânea , Administração Oral , Idoso , Endométrio/efeitos dos fármacos , Estrogênios/normas , Feminino , Humanos , Pessoa de Meia-Idade , Progestinas/normasRESUMO
We describe a project, participated in by 24 institutions in The Netherlands and Belgium, to determine normal reference values for steroids in urine by capillary gas chromatography. Urine samples from 288 healthy volunteers were analyzed in triplicate. Reference values, expressed in mumol/24 h, were determined for androsterone, etiocholanolone, dehydroepiandrosterone, 11-keto-androsterone, 11-keto-etiocholanolone, 11-hydroxyandrosterone, 11-hydroxyetiocholanolone, pregnanediol, pregnanetriol, 11-desoxytetrahydrocortisol, tetrahydrocortisone, tetrahydrocortisol, allo-tetrahydrocortisol, and 17-keto- and 17-hydroxysteroids. We also determined reference ratios for etiocholanolone/androsterone, tetrahydrocortisone/tetrahydrocortisol, and tetrahydrocortisol/allo-tetrahydrocortisol; an upper limit of a discriminant function to establish polycystic ovarian disease; and reference values for 24-h urine volume and creatinine excretion. Reference values were determined separately for men and women, each in six age categories: 0-3 months, 4 months-12 years, 13-16 years, 17-50 years, 51-70 years, and older than 70 years. We conclude that these reference values are reliable and form a basis for quantitative interpretation of steroid profiles.
Assuntos
Androgênios/urina , Química Clínica/normas , Hidroxicorticosteroides/urina , Progestinas/urina , Esteroides/urina , Adolescente , Adulto , Fatores Etários , Idoso , Androgênios/normas , Bélgica , Criança , Pré-Escolar , Cromatografia Gasosa/normas , Cromatografia Líquida de Alta Pressão , Feminino , Humanos , Hidroxicorticosteroides/normas , Lactente , Recém-Nascido , Laboratórios/normas , Masculino , Pessoa de Meia-Idade , Países Baixos , Progestinas/normas , Controle de Qualidade , Valores de Referência , Fatores SexuaisRESUMO
In 1980, an FDA advisory committee found inconclusive the evidence that the safety of oral contraceptives was related to their steroid content. In 1988, another FDA advisory committee examining the same evidence concluded that there is a trend to suggest such a relationship. The present review critically examines the published evidence and concludes that there is no scientific support for the suggestion that higher-dose oral contraceptives are less safe. Nevertheless, such products are no longer being made available in the United States.
Assuntos
Anticoncepcionais Orais Combinados/efeitos adversos , Estrogênios/efeitos adversos , Anticoncepcionais Orais Combinados/normas , Estrogênios/administração & dosagem , Estrogênios/normas , Europa (Continente) , Feminino , Humanos , Progestinas/administração & dosagem , Progestinas/efeitos adversos , Progestinas/normas , Estados Unidos , United States Food and Drug AdministrationRESUMO
PIP: Potential risks of prescribing generic drugs for oral contraception, ovulation induction and menopausal estrogen substitution are reviewed. In the U.S. all 50 states permit or require generic substitution, unless the prescription states otherwise. F.D.A. guidelines allow the bioavailability to range within 25%, i.e., the circulating level of drug in male test subjects after a single dose must be within + or - 25% of the range reported with the pioneer drug. Thus if a patient renews her prescription monthly she may receive a 50% range in dose level if different generics with both extremes in bioavailability are provided. Potential ranges for women, ill or elderly may vary even more. The potential risks for oral contraceptives are unwanted pregnancy, breakthrough bleeding, blood lipid elevation and less serious consequences such as minor side effects or confusion over package design. Risks for generic estrogen replacement include lack of protection from cardiovascular disease or osteoporosis and lack of therapeutic effect on menopausal symptoms; those from progestins are atherogenesis and failure to stop dysfunctional bleeding, ending in an unnecessary D & C. Possible sequelae of generics for ovulation induction are multiple pregnancy and ovarian hyperstimulation resulting in hospitalization for acute massive ovarian enlargement or rupture, as well as extra months of expense for treatment and monitoring. The most pressing concern is liability for the physician or pharmacist related to provision of generics. In most cases even 1 additional office visit for drug dose adjustment will obviate all savings accrued from taking generics.^ieng